Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:oral hydroxychloroquine sulfate tablets
Control group:Conventional treatment meet the Guideline
Sponsors
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old and above; 2. Meet the novel coronavirus pneumonia (COVID-19) diagnostic criteria. The upper and lower respiratory tract RT-PCR confirmed that 2019-nCoV nucleic acid positive, chest CT imaging examination could be used in conjunction; 3. SaO2/SpO2=94% under indoor air, or PaO2/FiO2<300mgHg (for severe type patients); 4. Sign informed consent; 5. Do not participate in the clinical study of other study drugs within 28 days.
Exclusion criteria
Exclusion criteria: 1. Aged less than 18 years old; 2. Other serious medical diseases such as malignant tumor, heart, liver and kidney disease, uncontrollable metabolic disease, etc; 3. Not suitable for gastrointestinal administration; 4. Pregnant or lactating women; 5. Those who are allergic to the ingredients of this product; 6. Mental state can not cooperate with the observer or cognitive impairment; 7. Severe liver disease (such as child Pugh score >=C, AST > 5 times ULN); 8. Patients with known severe renal impairment (creatinine clearance rate <=30 ml/min) or continuous renal replacement therapy, hemodialysis, peritoneal dialysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral nucleic acid test; | — |
Countries
China
Contacts
Public ContactGuochao Shi
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed